Navigation Links
Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)

AMSTERDAM, Nov. 28 /PRNewswire/ -- Oncology focused biopharmaceutical company Kiadis Pharma announces today that Andrea Velardi, M.D., Professor of Clinical Immunology at the University of Perugia, Italy and Kiadis Pharma are continuing their collaboration on ATIR(TM), a product in clinical development for enabling the use of a mismatched donor in a bone marrow transplantation by preventing acute Graft versus Host Disease (GvHD) for end stage leukemia patients. Under the agreement Professor Velardi will continue the development on the selective depletion of allo-reactive T cells from mismatched donors using Kiadis Pharma's ATIR(TM). Kiadis Pharma is preparing for a multi-center pivotal study on ATIR(TM) to start early 2009 and Professor Velardi will participate in this upcoming study.

"We are very pleased with our continued collaboration with the University of Perugia and Professor Velardi, who is a leader in the field of mismatched bone marrow transplantations," says Dr. Manja Bouman, CEO of Kiadis Pharma. "This collaboration is an important milestone in the development of ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients."

Professor Andrea Velardi says: "So far, we have treated 25 blood cancer patients who have received bone marrow from mismatched donors, including donor immune cells that are selectively depleted of cells causing acute Graft versus Host Disease using the ATIR(TM) process. The results so far are promising and I am therefore very pleased to continue to work with Kiadis Pharma in this field."

For the complete press release please go to:

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
(Date:10/12/2015)... , October 12, 2015 cell ... 6.49 billion by 2022, according to a new report by ... attributed to rise in incidence of oncology diseases and other ... is expected to reach USD 6.49 billion by 2022, ... This growth in demand can be attributed to rise in ...
(Date:10/12/2015)... 2015  Patara Pharma, a clinical-stage biotechnology company ... and conditions, today announced the closing of a ... with the close of its sale of preferred ... Security Agreement with Silicon Valley Bank whereby the ... will use the funds from the financing to ...
(Date:10/12/2015)... , Belgium , Oct. 12, 2015 /PRNewswire/ ... that full results from a completed clinical study of its ... have been published in the online issue of Clinical ... The peer-reviewed study was conducted in collaboration with ... led by Roland Andersson , MD, PhD, Professor of ...
(Date:10/12/2015)... ... October 12, 2015 , ... LifeTrak , a leader in ... Zoom, the world’s first amphibious fitness tracker that seeks to meet the needs of ... accurate heart rate monitoring both in water and on land, making it ...
Breaking Biology Technology:
(Date:10/13/2015)... Research and Markets ( ) has announced the ... Market - Estimation & Forecast (2015-2020)" report to ... --> The biometric market value is anticipated to ... in 2020 at an estimated CAGR of 16.47% from ... . Growing digitization in the government sector is expected ...
(Date:10/12/2015)... DUBLIN , Oct. 9, 2015 Research ... of Wintergreen Research, Inc,s new report "Biometrics: Market ... offering. --> --> ... overview of the Biometrics market segment. Research represents a ... most relevant and cogent market materials, with selections made ...
(Date:10/12/2015)... 12, 2015 Research and Markets ( ... "Iris Recognition Market by Component (Hardware & ... & Others), Industry (Travel & Immigration, Military & ... to 2020" report to their offering. ... Iris Recognition Market worth 3627.90 Million USD by ...
Breaking Biology News(10 mins):